Impact of different model structure and prior distribution in continual reassessment method

DOI10.1080/03610918.2018.1476698MaRDI QIDQ5087922zbMATH OpenOpenAlexFDO

Authors Efehan Ulas, Filiz Karaman, Tuba Koç

Publication date 4 July 2022

Published in Communications in Statistics. Simulation and Computation (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/03610918.2018.1476698

zbMATH Keywords

clinical trialsmaximum tolerated dosephase Idose-response models

Mathematics Subject Classification ID

Statistics (62-XX)

Recommendations

• Consistency of continual reassessment method under model misspecification
• A simple technique to evaluate model sensitivity in the continual reassessment method
• Characterization of the likelihood continual reassessment method
• A note on the robustness of the continual reassessment method
• Curve-free and model-based continual reassessment method designs

Cites work

• A Curve‐Free Method for Phase I Clinical Trials
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Bayesian model averaging: A tutorial. (with comments and a rejoinder).
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Group sequential and adaptive designs -- a review of basic concepts and points of discussion
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Describes a project that uses

Uses Software

• bcrm

This page was built for publication: Impact of different model structure and prior distribution in continual reassessment method

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5087922)